Zymeworks Inc. shared a post on LinkedIn:
“Raffaele Colombo, PhD, Zymeworks Associate Director for Medicinal Chemistry—along with Matthew Vogel and Paolo Tarantino, MD, PhD of the Dana-Farber Cancer Institute and Harvard University — have published a paper called “Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates” in the American Society of Clinical Oncology (ASCO) Journal of Clinical Oncology. As ADCs experience tremendous expansion as cancer therapies, the paper dives into the latest evidence on their mechanism of action and rich complexity.”
Title: Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
Authors: Matthew Vogel, Raffaele Colombo, Paolo Tarantino
Read the Full Article.
More from Zymeworks Inc. on OncoDaily.